Journal
CANCER TREATMENT REVIEWS
Volume 35, Issue 3, Pages 255-261Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2008.11.001
Keywords
Microtubule; Microtubule-targeting agent; Taxane; Vinca alkaloid; Colchicine; Epothilone; Taccalonolide; Discodermolide; 2-Methoxyestradiol; Halichondrin B
Categories
Funding
- National Cancer Institute [CA121138]
- NCI [P30 CA054174]
- Institute for Drug Development ATT Endowed Chair
- NATIONAL CANCER INSTITUTE [P30CA054174, R01CA121138] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Drugs that affect microtubule dynamics, including the taxanes and vinca alkaloids, have been a mainstay in the treatment of leukemias and solid tumors for decades. New, more effective microtubule-targeting agents continue to enter into clinical trials and some, including the epothilone ixapebilone, have been approved for use. In contrast, several other drugs of this class with promising preclinical data were later shown to be ineffective or intolerable in animal models or clinical trials. In this review, we discuss the molecular mechanisms as well as preclinical and clinical results for a variety of microtubule-targeting agents in various stages of development. We also offer a frank discussion of which microtubule-targeting agents are amenable to further development based on their availability, efficacy and toxic profile. (C) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available